View
214
Download
1
Tags:
Embed Size (px)
DESCRIPTION
A publication for community physicians, a first look at Banner MD Anderson's new head and neck cancer and stem cell transplant programs.
Citation preview
BY JAKE POINIER
W ith the arrival of 2013,
Banner MD Anderson
Cancer Center in Gilbert
will be expanding its world-class offer-
ings in two key areas: Head and neck
cancer surgeries and oncology, and
stem cell transplantation. While the
programs are different from a medical
perspective, they have one essential
element in common: integrated
teams with national expertise in their
respective fields.
“Integration is one of the important
things that makes the Banner MD
Anderson approach different,” says
head and neck surgeon Thomas D.
Shellenberger, M.D., who has helped
start up the program. He has been both
at The University of Texas MD Ander-
son Cancer Center and MD Anderson
Cancer Center Orlando for a decade,
where he headed up the creation of
their head and neck program. “Rela-
tive to other cancers, head and neck
cancer requires numerous disciplines
and subspecialties in addition to radia-
tion oncology, medical oncology, and
surgery in order to be successful.”
For example, Dr. Shellenberger
cites speech pathology, dental oncol-
ogy, and nutritional consultation, as
well as collaboration with plastic and
reconstructive surgeons. “It’s not just
about curing the cancer, but how can
we help patients retain maximum
quality of life,” he says.
JANUARY 2013A PUBLICATION FOR COMMUNITY PHYSICIANS
Thomas D. Shellenberger M.D. and Klaus Wagner M.D.
INSIDE2 Stem cell program, transplant options3 Changing the surgical landscape4 Meet Drs. Craft and Tan5 New hope for pancreatic cancer patients
6 What’s happening at Banner MD Anderson7 Rare pregnancy cancer is curable8 Banner MD Anderson physicians
Integrated approachesFirst look at Banner MD Anderson Cancer Center’s new head and neck cancer and stem cell transplant programs
2 JANUARY 2013 ROUNDS
HEAD AND NECK CANCERKlaus Wagner, M.D., the team’s medical
oncologist, notes an increasing preva-
lence of head and neck cancer. “In the
past, these types of tumors were smok-
ing and alcohol related,” he says. “We’re
seeing more head and neck cases that
are HPV related, and we’re also seeing
them in younger patients.”
The head and neck program will be
increasing its capabilities in the coming
year, including the addition of robotic
surgery. On the oncology side, Dr. Wagner
will be adding state-of-the-art diagnostic
imaging as well as multimodality thera-
pies such as monoclonal antibodies.
“Cetuximab can be a good alternative to
chemotherapy, with fewer side effects, or
as a synergizer with radiation, particu-
larly for those who have tolerance issues
with chemotherapy,” he said.
Finally, the program will be launch-
ing prospective research trials in 2013.
“Head and neck cancers really don’t
form one disease but a group of diseases
that are individually rare, so there’s a lot
of heterogeneity,” Dr. Shellenberger says.
“We will be studying
treatment regimens
to determine which
ones lead to im-
proved outcomes,
with specific strate-
gies to objectively
study quality indica-
tors in a prospective
way to chart the
course of how the
program develops. The head and neck
program at MD Anderson Houston is a
world leader, and our task is to follow
that lead and meet that high standard.”
STEM CELL TRANSPLANT PROGRAMThe launch of the Stem Cell Transplant
program offers new hope for Arizonans
with leukemia, lymphoma, multiple
myeloma, myelodysplastic syndrome,
and other hematologic and bone mar-
row failure disorders. Heading up the
program is Gorgun Akpek, M.D., M.H.S.,
a nationally recognized stem cell
transplant physician whose background
includes work with the Bone Marrow
Transplantation program at Johns Hop-
kins University and the University of
Maryland Greenebaum Cancer Center,
an NCI-designated cancer center.
“I’m excited to translate my experi-
ence and background into building
a program in a timely fashion and
providing the best transplant care in
Arizona,” Akpek says. “We’re currently
in the process of aligning our guidelines
and standard operating procedures
with MD Anderson, since we have very
similar treatment goals and care sets.”
Akpek expects to announce trans-
Javier Munoz M.D., and Gorgun Akpek M.D., M.H.S.
plant activities starting in January or
February, and is in the process of hiring
two additional transplant physicians. The
program will start with autologous trans-
plants, using a patient’s own stem cells.
Allogeneic transplants, using cells from a
related or matched donor, are expected
to be added by summer 2013.
TRANSPLANT OPTIONS The upper age for eligibility is expected to
be 75 for autologous transplants and 70 for
allogeneic transplants, with the possibility
of increasing those ages in the future.
The transplant program will work in
concert with Javier Munoz, M.D., staff
physician in hematology and oncol-
ogy who has trained at MD Anderson
Houston, and handles patients with
hematological malignancies including
lymphomas, many of whom eventu-
ally need transplants. “Lymphoma is
a heterogeneous disease, and there
are multiple variables that determine
which patients will truly benefit from a
particular treatment including targeted
therapy with monoclonal antibodies or
antibody-drug conjugates,” said Munoz.
“We formed a hematology tumor board
in which different specialists review cases
in a multidisciplinary fashion to tailor the
best treatment regimen for each patient.”
Optimally, physicians should refer
patients to Akpek for a transplant consul-
tation early in the course of the disease.
“Most of the time we are a last resort,
after many treatments and after the dis-
ease becomes resistant,” he says. “Even
if a patient doesn’t meet the criteria, the
earlier the referral the better.”
It’s not just about curing
the cancer, but how can we help
patients retain maximum
quality of life.
— Thomas D. Shellenberger, M.D.
DID YOU KNOW?MD Anderson Houston is one of the largest centers in the world for stem cell transplants — performing more than 865 procedures for adults and children each year, more than any other center in the nation.
DID YOU KNOW?According to the American Cancer Society, more than 52,000 men and women in the U.S. were diagnosed with head and neck cancers in 2012.
BannerMDAnderson.com 3
BY DEBRA GELBART
Two plastic surgeons at Banner
MD Anderson Cancer Center in
Gilbert recently began perform-
ing the latest in autologous breast recon-
struction surgery for cancer patients.
Unlike a TRAM flap that depends
on the rectus for a blood supply when
the tissue is relocated, the Deep Inferior
Epigastric Perforator (DIEP) reconnects
abdominal skin and fat to the internal
mammary artery. The rectus is left intact.
A by-product of the procedure is
improved abdominal contour, which en-
genders increased patient satisfaction.
Changing the surgical landscapeNew era in autologous breast reconstruction comes to Banner MD Anderson Cancer Center
GIVING PATIENTS MORE OPTIONS“The DIEP has not been widely avail-
able before now,” said reconstructive
surgeon Benny Tan, M.D. “We want
to give more patients an opportunity
to choose this approach to breast re-
construction.” He and reconstructive
surgeon Randall Craft, M.D. typically
perform the surgery together.
Both practice in Banner MD
Anderson’s Division of Surgical Oncol-
ogy as plastic and reconstructive
surgeons. Unilateral reconstruction
takes between six and eight hours;
bilateral reconstruction can take up
to 12 hours.
With a traditional TRAM flap, the
surgical impact on the rectus often
results in bulging of the abdomen,
hernias or weakness, Drs. Tan and
Craft said. “But by leaving the rectus
intact,” Dr. Craft said, “we can often
give patients a better quality of life.”
NO AUTOMATIC AGE RESTRICTIONNot all patients are candidates for
the DIEP, Dr. Tan said, explaining
that sometimes a patient’s vessels
are too small to accommodate the
reattached tissue. “Although there
is no age cutoff,” he said “a patient
must be physiologically fit enough
4 JANUARY 2013 ROUNDS
to endure a six-to-12-hour surgery,
depending on whether the recon-
struction is unilateral or bilateral.”
A patient can’t be morbidly obese
or especially thin. Her ideal BMI is
between 25 and 35, he said, so that
she has enough abdominal tissue to
be used for the reconstruction. And,
ideally, she has not had previous
abdominal surgery, although a C-
section or a previous hernia surgery
or laparoscopic cholecystectomy, for
example, would not preclude a DIEP.
The post-surgical hospital stay is
typically four to seven days.
This procedure is well-suited
for a patient who has undergone
radiation therapy, Dr. Craft said.
Susan Brown*, 50, of Chandler, had
been a radiation therapy patient,
so she wasn’t a good candidate for
implant surgery. She was referred
to Dr. Craft for the DIEP. “I would
tell other breast cancer patients to
strongly consider this procedure,”
Brown said. “It’s tough, because of
the length of the surgery, but it’s well
worth it. I am so grateful to have a
natural-looking and natural-feeling
breast again and I really like knowing
I won’t need another surgery in 10
years like I would with an implant.”
For patients who are not good
candidates for the DIEP, Drs. Craft
and Tan perform autologous breast
reconstruction options, including
the latissimus dorsi flap, TRAM flaps
and implant reconstruction.
Drs. Craft and Tan estimate that
between 25 and 40 percent of all
breast reconstruction patients ulti-
mately will choose the DIEP for their
breast reconstruction. Even if they are
good candidates for the procedure,
however, some patients will opt for
implant surgery or another autolo-
gous reconstruction surgery because
of the complexity of the DIEP.
* Not patient’s real name.
Randall Craft, M.D. became interested in the Deep Inferior Epigastric Perforator (DIEP) procedure while he was a surgical resident in the Harvard Plastic Surgery Combined Residency Program in Boston, Mass. “They did a high volume of these in the Harvard system,” he said, “and I was able to learn a lot about the procedure. Since then, I’ve published a lot about it in the medical literature.” Dr. Craft, who is board-certified in surgery, said he’s always “been drawn to the creativity of plastics. “There’s nothing routine about it, and I like the reconstruc-tive aspects of this type of surgery.” Most of his patients undergo breast reconstruc-tion, but he also performs reconstructive surgery on any part of the body affected by cancer. After graduating from medical school at The Ohio State University College of Medicine in Columbus, he completed his general surgery residency at Mayo Clinic Arizona before beginning his plastic surgery residency at Harvard. He also completed a combined research and clinical fellowship at the Bernard O’Brien Institute of Microsurgery in Melbourne, Australia. Dr. Craft said the most rewarding aspect of performing the DIEP is “provid-ing an opportunity for women to have their sense of self restored,” he said, “without having a foreign body inside them. “The DIEP preserves the symmetry of the chest and patients are typically quite happy with the outcome.”
Benny Tan, M.D. was born and raised in Singapore. At 21, he went to Ireland to attend medical school. After graduation and a general surgery and orthopedic surgery residency, he came to the United States and completed a three-year general surgery residency at Johns Hopkins Hospital in Bal-timore, followed by two years of a general surgery residency at Massachusetts General Hospital in Boston. He then completed an orthopedic hand and microsurgery fellow-ship at Jackson Memorial Hospital in Miami, Fla., followed by a plastic surgery residency at the Cleveland Clinic Florida in Weston, Fla. He is board certified in plastic surgery and general surgery. “I performed many types of reconstruc-tive surgery,” Dr. Tan said, “but I gravitated toward breast reconstruction because the patients are so appreciative when we’re able to give them back their normal life.” He said he began performing the DIEP procedure at Banner MD Anderson because of patient demand. Like Dr. Craft, Dr. Tan also performs implant- and autologous-based breast reconstruction. Dr. Tan noted that DIEP patients also appreciate the extra benefit of the tummy tuck that comes with the procedure. He said both the chest and abdominal scars are well-tolerated by patients. “They also like that their abdominal contour is improved,” he said. “It’s a change most patients are very happy with.”
Contact Drs. Tan and Craft at 480-256-3609.
Doctors well-trained, skilled in performing DIEP
BannerMDAnderson.com 5
BY BETH LIPHAM
I nnovative treatments and a
brighter sense of hope are on the
horizon for pancreatic cancer
patients as Banner MD Anderson
Cancer Center in Gilbert begins a
series of clinical trials.
Pancreatic cancer is one of the
deadliest cancers of our time, with
approximately 42,000 new cases diag-
nosed annually in the United States
resulting in 35,000 deaths. Diagnos-
ing pancreatic cancer is difficult
because symptoms such as low back
pain, indigestion and gastrointestinal
complaints could be mistaken for
other common conditions such as
peptic ulcer, gastritis or arthritis. Un-
fortunately, once detected, pancre-
atic cancer is often advanced and not
curable. Only 20 percent of patients
are candidates for surgery, and only
20 percent of those that have surgery
survive up to 5 years after diagnosis.
PATIENT ACCESSTomislav Dragovich M.D., division
chief of Medical Oncology and Hema-
tology, feels patients with this deadly
disease should be offered access
to clinical trials because standard
therapies are just not good enough.
Current research focuses on breaking
down the complex genetic code of
pancreatic cancer and finding
new anti-cancer drugs (“targeted
therapies”) for pancreatic cancer.
“We are just beginning to see
the fruition of years of continued
research efforts with some more
recent studies showing promise,”
Dragovich says. “A combination
regimen called FOLFIRINOX, for the
first time extended the survival of
patients with metastatic pancreatic
cancer to beyond 11 months. This is
now accepted as a good option for
some patients (those with a good
performance status). And adding
a new drug, nab-paclitaxel (Abrax-
ane), to the current standard therapy
(gemcitabine) also appears to extend
survival of patients with metastatic
disease.
“The complete results from this
trial will be presented at a national on-
cology meeting (ASCO GI Symposium)
in January,” say Dragovich, who par-
ticipated as an investigator in this trial.
“These are incremental but significant
improvements for our patients.”
RESULTS ARE ENCOURAGINGThe Banner MD Anderson team is en-
couraged by the pace of new research
concepts introduced for patients
with pancreatic cancer. Some of the
research treatments are now available
at Banner MD Anderson. Dragovich
is the principal investigator on two
such trials for patients in whom the
standard treatment has failed.
The first trial investigates an
anti-cancer drug called MM398. This
is a chemotherapy drug packaged in
nano-liposomes, which coat the drug
to allow for better penetration inside
pancreatic cancer tissue.
The second trial is a radio-immu-
notherapy trial. It exploits a novel ap-
proach where antibodies are tagged
with a radioactive head that links to a
protein (PAM4) on the surface of the
pancreatic cell much like a “lock and
key” system. “The antibody attaches
to the cancer cell and unloads the
radiation to selectively target and kill
cancer cells,” Dragovich says.
While these are promising and
intriguing concepts, they still need
to be proven in clinical trials. “We
are proud to offer state-of-the art
treatment but also to go beyond that
and provide access to clinical trials
to patients suffering from this dis-
ease. We are encouraged with some
recent results generated by clinical
trials,” he says.
To refer a patient, contact Banner MD Anderson Cancer Center at 480-256-3433. To learn more about pancreatic cancer therapy, read Dragovich’s recent review online at emedicine.medscape.com/article/280605-treatment. He can be reached at 480-256-3335.
New hopefor pancreatic cancer patientsCancer clinical trials open at Banner MD Anderson Cancer Center
Tomislav Dragovich M.D.
6 JANUARY 2013 ROUNDS
T he start of a
new year is a
time to con-
sider our personal
and professional
goals, to reflect and
to dream.
Our patients
will resolve to live
better and to fight
their cancer, and it is our privilege
to stand by them and arm them
with the tools to survive and thrive.
One reason we’re so successful at
Banner MD Anderson Cancer Center
in Gilbert is because of our focus on
the continuum of care.
We are not isolated providers.
We are a team that works together.
Physicians, nurses, researchers,
pharmacists and staff are all es-
sential, because without this team
approach to cancer care, the quality
of care suffers.
From the very first diagnostic test
to treatment and beyond, excellent
communication is critical to pro-
viding outstanding care along the
continuum. One place we see this
working very well is with our gyne-
cologic oncology program, led by
Diljeet Singh, M.D.
In the past, the Valley has been
traditionally underserved in this
area. But with this program and our
experienced gynecologic oncologists,
we are changing that. The presence
of large specialty medical centers like
ours helps to ensure that patients can
experience the continuum of care
— working with the same team from
diagnosis through survivorship. Plus,
with the growth of the gynecologic
oncology program, we also expect to
bring more clinical trials to the Valley.
As we look ahead to this year,
I’m also excited to see the Banner MD
Anderson Stem Cell Transplant pro-
gram continue to grow and evolve
under the leadership of Gorgun
Akpek, M.D. It’s a tremendous step
forward to be able to offer this to
patients with leukemia, lymphoma,
multiple myeloma and other hemato-
logic conditions stem cell transplanta-
tion as part of their treatment.
I’m also eager to watch as our
head and neck program, led by
Thomas Shellenberger, M.D.,
continues to grow as well. In fact,
this March, we expect to see another
surgeon join the team, which already
includes talented radiation and
medical oncologists, allowing us to
offer a full range of care.
This year promises to be an
exciting one, and each and every
one of you plays a critical role in the
continuum of care and the quality
of care we as a team provide. Thank
you for all you do, and I look forward
to building on our successes in 2013!
Sincerely,
Edgardo Rivera, M.D.Medical Director
What’s happening at Banner MD Anderson Cancer Center
BY DR. EDGARDO RIVERA, MEDICAL DIRECTOR
BannerMDAnderson.com 7
BY BRIAN SODOMA
There are plenty of concerns for
a mother to be. Unfortunately
there are also those rare in-
stances when thinking about cribs and
diapers is suddenly cancelled out by
cancer treatment.
That’s the case with the rare but
curable Choriocarcinoma, a type of Ges-
tational Trophoblastic Neoplasia (GTN).
ABNORMAL ACTIVITYGTN occurs when placental tissue
grows abnormally during a pregnancy.
The most common type of GTN is a
hydatidiform mole, also known as a
molar pregnancy. In rare cases, molar
pregnancies can become malignant,
leading to choriocarcinoma.
“The good thing is [choriocarci-
noma] is very sensitive to chemother-
apy. Even stage three can be cured,”
says Dr. Matthew Schlumbrecht, a
gynecologic cancer specialist at
Banner MD Anderson Cancer Center
in Gilbert who has seen about
15 choriocarcinoma cases in his career.
GTN occurs in about 2 in 1,000 preg-
nancies, with choriocarcinoma being
only a small fraction of GTN cases. In all
cases of GTN, the pregnancy is nonviable.
But the good news is that most women
can conceive again after treatment. There
is no prevention strategy for choriocarci-
noma. More than anything, the condition
seems to be a case of bad luck.
SEEING THE MARKERSDoctors are usually tipped off to the
condition during an ultrasound, which
will reveal abnormal tissue in the
uterus. A blood test showing high hCG
(beta human chorionic gonadotropin)
levels is the biggest clue. Abnormal
vaginal bleeding, pelvic pain, and an
abnormal uterine size can also be
present. During treatment, βhCG levels
are monitored closely as a sign that
the condition is receding. Though rare,
GTN can recur after initial diagnosis,
so it is important that patients follow
up closely with their doctors.
Those at greatest risk for the condi-
tion are Asian women, folate-deficient
women, and those having babies at the
extremes of child-bearing age, either
under 20 or over 45 years. Obstetri-
cian/gynecologists are well-trained
at detecting the disease, according to
Schlumbrecht, who also said only a
small number of patients with GTN
even require chemotherapy.
“Most patients end up doing really,
really well with this,” he says.
Rare pregnancy cancer
is curable Choriocarcinoma occurs in 2 of 1,000 pregnancies
The good thing is [choriocarcinoma] is very sensitive to chemotherapy. Even stage three can be cured.
— Dr. Matthew Schlumbrecht
Going into medicine was an easy choice for someone like Dr. Matthew Schlumbrecht. The gynecological cancer specialist at Banner MD Anderson in Gilbert was driven by the intellec-tual challenge and a desire to help others.
Today, Schlumbrecht finds great intel-lectual challenge specializing in malignan-cies of the female genital tract. He has been awarded The University of Texas MD Anderson’s Jesse H. Jones Fellowship Award for excellence and unique contribu-tions to cancer education and has also won MD Anderson’s Gynecologic Oncol-ogy Fellow of the Year recognition.
Schlumbrecht is also working on doctor-focused cancer survivorship research. He has conducted numerous surveys of primary care physicians, internists and those in other disciplines, asking them to assess their strengths and weaknesses in working with cancer survivors.
By 2020, there will be some 20 million cancer survivors in the U.S. After success-ful treatment, these patients must then use these primary care physicians, internists and other disciplines for their health care needs instead of their oncologists, a transition, Schlumbrecht says, that can be difficult.
“There’s a lot of anxiety for patients leaving their oncologist. It’s a much more complicated problem than one would think,” he said.
He is also working to establish a robotic surgery database for the surgery division at Banner MD Anderson to conduct research in the rapidly growing field of minimally invasive surgery. Partnered with MD Anderson’s Houston facility, the data from such a venture will aid in tracking patient outcomes from new surgical approaches.
Meet Dr. Matthew Schlumbrecht
PRESORTED STD
U.S. POSTAGE
PAID
LONG BEACH, CA
PERMIT NO.1677
Banner MD Anderson Cancer Center Physicians
HEMATOLOGY & MEDICAL ONCOLOGY SECTION
Tomislav Dragovich, M.D., PhD, Division Chief Digestive tract cancers including colorectal, esophageal, stomach, pancreatic, hepatobiliary
Gorgun Akpek, M.D., M.H.S.Director of Stem Cell Transplantation and Cellular Therapy program
Shakeela Bahadur, M.D.Lung, colorectal, breast cancers
Mary Cianfrocca, D.O.Breast Cancer Program Director
Farshid Dayyani, M.D., PhDGenitourinary and Gastrointestinal cancers
Jade Homsi, M.D.Melanoma, sarcoma, immunotherapy
H. Uwe Klueppelberg, M.D., PhDMultiple myeloma and other plasma cell disorders, lymphomas, myelodysplastic syndrome, brain cancers, head and neck cancers, thoracic cancers
Javier Munoz, M.D.Lymphoma and other blood cancers
Edgardo Rivera, M.D. Medical Director Breast cancer
Kerry Tobias, DOPain management, palliative medicine, physical medicine, rehabilitation
Klaus Wagner, M.D., PhDThoracic and Head & Neck Cancers
Bryan Wong, M.D.Genitourinary cancers ONCOLOGY SURGERY SECTION
Judith K. Wolf, M.D. Division Chief Gynecologic oncology
Stephanie Byrum, M.D.Breast surgery
Al Chen, M.D.General Surgery
Randall Craft, M.D.Full spectrum of both implant-based and autologous breast reconstruction, comprehensive plastic and reconstructive options for all areas of the body
Mark Gimbel, M.D.Melanoma, sarcoma, cancer of the stomach, small bowel, colon and rectum, thyroid, pancreas, liver and other rare cancers
Matthew Schlumbrecht, M.D., M.P.H.Gynecologic oncology; gestational trophoblastic disease; a variety of surgical techniques including radical abdominopelvic exploration and minimally invasive procedures.
Rob Schuster, M.D.General surgery
Thomas Shellenberger, M.D. Recurrent thyroid cancers, cancers of the oral cavity, oropharynx, and larynx, salivary gland cancers, advanced skin cancers and melanoma of the head and neck, complications from treatment of head and neck cancer.
Diljeet Singh, M.D.Program Director, Gynecologic Oncology; Program Director, Cancer Prevention & Integrative Medicine
Benny Tan, M.D.Plastic and reconstruction surgeonBreast cancer reconstruction and most forms of cancer reconstruction
RADIATION ONCOLOGY SECTION
Matthew Callister, M.D. Division ChiefGastrointestinal, skin, sarcomas and head and neck cancers
Dan Chamberlain, M.D.Thoracic and head and neck malignancies, and body radiosurgery
Emily Grade, M.D.Breast treatment including partial breast brachytherapy, prostate brachytherapy, gynecological and thyroid cancers
Terence Roberts, M.D., J.D.Brain, lung and prostate tumors; stereotactic radiosurgery; partial breast brachytherapy
DIAGNOSTIC IMAGING SECTION
Donald Schomer, M.D. Division Chief CAQ Neuroradiology Oncologic diseases of the brain, spine, head and neck
John Chang, M.D., PhDAdvanced MR and CT imaging of gastrointestinal and genitourinary systems; imaging guided biopsies
Vilert Loving, M.D.Breast imaging and intervention
Harvinder Maan, M.D. CAQ NeuroradiologyDirector of Neuroradiology Neuroradiology and interventional spine procedures
Rizvan Mirza, M.D.Abdominal and pelvic magnetic resonance imaging
Susan Passalaqua, M.D.Director of Nuclear Medicine and Molecular Imaging Oncologic imaging, nuclear medicine, radiology, PET/CT
Andrew Price, M.D., C.A.Q. Interventional radiology, including percutaneous tumor ablation, chemoembolization, and radioembolization David Russell, M.D., F.A.C.P.Breast imaging and intervention
CRITICAL CARE SECTION
Shiva Birdi, M.D., Division ChiefJijo John, M.D.Deven S. Kothari, M.D.Dean Prater, M.D.Ravindra Gudavalli, M.D.
INTERNAL MEDICINE SECTION
Nikunj Doshi, D.O., Division ChiefShefali Birdi, M.D.David Edwards, M.D.Ronald Servi, D.O.
PATHOLOGY SECTION
Kevin McCabe, D.O. Division Chief
Banner MD Anderson Cancer Center in Gilbert physicians are highly specialized in
their fields of expertise. Below is a listing of physicians currently on our full time staff.
Physicians continue to join Banner MD Anderson, so this list will continue to evolve.
To make a referral to a physician on our staff, please call 480-256-3433. To contact a member of medical staff, call 480-256-6444 and ask for the physician to be paged.